Regeneron Launches Phase III COVID-19 Prevention Trial with ‘Antibody Cocktail’ REGN-COV2

A Phase III trial will study if REGN-COV2 can prevent infection in uninfected people who have had close exposure to a COVID-19 patient; and two Phase I/II/III trials will evaluate the drug in treating hospitalised and non-hospitalised patients with COVID-19.


Biospace Inc.